{"name":"Sanwa Kagaku Kenkyusho Co., Ltd.","slug":"sanwa-kagaku-kenkyusho-co-ltd","ticker":"","exchange":"","domain":"skk-net.com","description":"","hq":"Nagoya","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"1976-01-01","label":"Cephulac first approved","drug":"Cephulac","drugSlug":"lactulose","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"SK-1405","genericName":"SK-1405","slug":"sk-1405","indication":"Other","status":"phase_1"},{"name":"SK-1403","genericName":"SK-1403","slug":"sk-1403","indication":"Unknown","status":"phase_3"},{"name":"Upasita","genericName":"UPACICALCET","slug":"upacicalcet","indication":"Secondary hyperparathyroidism","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cephulac","genericName":"LACTULOSE","slug":"lactulose","indication":"Constipation","status":"marketed"}]}],"pipeline":[{"name":"Cephulac","genericName":"LACTULOSE","slug":"lactulose","phase":"marketed","mechanism":"Small molecule","indications":["Constipation","Hepatic encephalopathy","Hyperammonemia"],"catalyst":""},{"name":"SK-1405","genericName":"SK-1405","slug":"sk-1405","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SK-1403","genericName":"SK-1403","slug":"sk-1403","phase":"phase_3","mechanism":"SK-1403 is a small molecule drug that targets the molecular target.","indications":["Unknown"],"catalyst":""},{"name":"Upasita","genericName":"UPACICALCET","slug":"upacicalcet","phase":"marketed","mechanism":"Extracellular calcium-sensing receptor","indications":["Secondary hyperparathyroidism"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQNE9rb0hlUG9RLVNiR3NmVHdJajRMc09SR01Zekxaa1RfQ3pmTm5HMVkzTVdGVkNpMFFCQjNmdU1LYjF5NEp4Q3pyVHlQMjRfZkpKSGlacEIwUkpiLVh6S0dWME5hTFRnVEh3WEl3ZFN5a1BPTy1OMGprR08yc3E4VWlzM1RMUU5lSGRUb0QtWjJzd3NiMEg5NkxaUEtjck5kYmwyeA?oc=5","date":"2026-04-02","type":"regulatory","source":"IndexBox","summary":"Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics - IndexBox","headline":"Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sUFVGQTlTaXJSeE54eTZsQk5rRnBONXNEeE1VQ0dkbmxEa2hjTEJLcUt1amtQdjVIR2xEOHl4YjA2SmdCbEJIU2VmazBLYlpuZUswN0Q2SnpfMTQ2S0k1cUotdllWaTBO?oc=5","date":"2025-10-09","type":"regulatory","source":"Wiley Online Library","summary":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study) - Wiley Onli","headline":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNWWJ2aTZhMmk1UE5zX2lqQkVkZHQ5TWpwa1p5d1NJcDZpcU1KOVF4WVBobjdGSDlkRlAxS0dGemRxUl9HY25ldmQ4UUc1QWR4VWNfOWI4dEprbHRhcVBCRWtMb1JielA4anB0SzM4TjR6bHhpdldaLTcyelNRMW9tVmhiU3JXLWgxczBJb2E3X203VFNDUnl2YzdvY245clZyanVN?oc=5","date":"2025-09-26","type":"pipeline","source":"BioWorld News","summary":"Room for growth in acromegaly as Crinetics’ Palsonify cleared - BioWorld News","headline":"Room for growth in acromegaly as Crinetics’ Palsonify cleared","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPcV9KRGtVNWV0emZlZDF4Y2g2ZjE0TVM5MGVtbWxVeC01UngxbXhhYXZ2dU0yT0lJT2c0TmNpUGZtNkNvdk5weDVTVjcxOS1mVk4xaHMyRDF5LVNnQXRseEo0aERZLVpLSGhGZHhEMzN1alN3c3BpTDJrLS1xRW5VM204djItY1g3NFZ1OTh5ZzRCWFp3?oc=5","date":"2023-10-18","type":"pipeline","source":"Frontiers","summary":"The role of chicken eggs in modulating sarcopenic obesity and gut microbiota in db/db mice - Frontiers","headline":"The role of chicken eggs in modulating sarcopenic obesity and gut microbiota in db/db mice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9JZ2xDejdNQmtEbUstN2xBUW1XN2cwaEt3S1JPWmg1VWlXaDRMWDdxQy1ya2FGTmRIWk9ZdmVrWWhJM3RaYXVZcHpQVG5pR3J5TWx5U29xQ3dVODhvMFNr?oc=5","date":"2023-09-05","type":"trial","source":"Nature","summary":"Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study - Nature","headline":"Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxNUGhPOHNHM0wtWk5MQjQ1a0VSU0JXZEl6XzJBLUNKVmtCSlFFekVycmd0NzBIbHRqMWhvMWdMdWdNa0o4UjJDQ3lXcjQyaDNVZEpwaDE4NU5Rcm9xc1A3VVd4VGIyR0pGWkl1VG9FQjFjSzJkWWJJQzAwUkVKZzRkOGktVjVDa3l5V1VJYldsV3llT2hoQ3VxMlR4Uy1XbHVRdTVKOUVuNHp4SU0wSi1BNVdyRVVlbkdvOFJlZjNScWxmeUUwTktLMnprYW4xX1dRc3A5c1J4M2hLbnJTU0dFTWtaX0xxOXFFWjE1X093aTBvSXh1a004bk5ZQjlTbnpaYnlwdGg4bElWR0VzN1RhZjFDWXlHaTI5S2NuWk5UVUpvbFZZbDlJV1g2NHBaZjBzMlVPRjQtVm5oeUVWUXQ5M1dhR3RMbWJCTDZFZHpMSnI?oc=5","date":"2022-02-28","type":"pipeline","source":"GlobeNewswire","summary":"Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter - GlobeNewswire","headline":"Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOYUlxdmNvTGx6RmJsb0F3QWFZWldPUTFkTXVRUHF1YU8wcURDcW9YN085Z3pTQVNkb3RSQ3AyVmY2ZmNoRVpYY3QtVWxhUEliMVd3VWtSckhLUDlQTEZMUk5yaUZvRWtSODZTRTJsSk9zc0lVSUpOZTNKSHdwNkgyakUzMS1LV2h1VWpxai03MTNIYWowOTBjc2hidUk3c2VqWjd2RWJtU0FkT3Q2dDhpV19hRkQ4UU4zaWtsVjJwMkY4cEFrR3VGZUpId251aVd1QmFYSjdnd2s?oc=5","date":"2018-10-08","type":"pipeline","source":"PR Newswire","summary":"Top 20 Pharmaceutical Wholesale & Distribution Organizations 2018 - Visiongain Report - PR Newswire","headline":"Top 20 Pharmaceutical Wholesale & Distribution Organizations 2018 - Visiongain Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE91V0xFY2x5Qy1lek5KV09Lb1FpclFYcEZYaVpDcnd4b2pBandBX0lVS1phVkNuczVudWFSMDhMdWZTY1ZpNGl0Tk40NW1QSk90S29N?oc=5","date":"2017-07-13","type":"pipeline","source":"Nature","summary":"Comprehensive risk management for the prevention of cerebro- cardiovascular diseases in Japan - Nature","headline":"Comprehensive risk management for the prevention of cerebro- cardiovascular diseases in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNa1FXM2hMdjlTeS1MSmpteDZQUlJFX1IzZmJJOEQzam5yLTNQNWZScl9SRXBJYlVodjRDUV85Tm5QaGxLdWJPQVFRclRweVlyN3RMZndKREM0V2EzUm5EaE9CeGhROFJUMURNQm5WaU11clNZTUlESzBfd2lfdS03NldyTkUwOVNnMUpXVEE5X0tkQWtya3M4M05laXFCa3pPUFhTQzJWMHZyZ3p1ZHNfVWlkM2hBN0gzZFhiN0piOG5QdXdva25sMVkzRk1hYnZaMXV1Z1BxT0JjYVdkOEZubjRn?oc=5","date":"2016-12-07","type":"pipeline","source":"finchannel","summary":"Astellas Launches Kiklin Granules, a Treatment for Hyperphosphatemia, in Japan - finchannel","headline":"Astellas Launches Kiklin Granules, a Treatment for Hyperphosphatemia, in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPTGVRbnhPMUM0M3hoRnJkNGFKYlY5TkFxREtXWmxQWElWeElPbm9VYTJ0b1BkeTlrOUxSbmhEMURJMW1BTHZkbDlodDlwUmsyMEk0YlZCNmpPQU1XTnk2elZNM2V4Vm1hLVd1cHdkZ0EtUDZqakRfdkhHblhROHV1WVhjcDNUSzFZOEE4?oc=5","date":"2013-06-17","type":"pipeline","source":"Pharmafile","summary":"Catalent breaks ground on $35m controlled-release facility - Pharmafile","headline":"Catalent breaks ground on $35m controlled-release facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPVzUzSXRqamFHLXVPYkZmaUlWOVJBZnY2ekt5aEJPY1plbWhfaHRPSXppRUVvUWhHcHE2WVZFeUZhRVhXcGNuNDA0U1FRcGwzaHNZUlEyVktDaTN2bDd4QXo3dHB4U0hCU3h2SXFaZzBpTUhZY0dqN2toNU9HdlBnaDEwNVhMQURnM2FXekJvcDFzSENxX3VnLWV3?oc=5","date":"2013-01-15","type":"pipeline","source":"BioSpectrum Asia","summary":"Astellas, Sanwa launch hyperkalemia treatment - BioSpectrum Asia","headline":"Astellas, Sanwa launch hyperkalemia treatment","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}